Announcements and Notices - [Other - Miscellaneous]

TransThera Sciences (Nanjing), Inc. develops and manufactures biopharmaceutical products. The Company produces oncology, inflammatory, and cardiovascular treatment drugs. TransThera Sciences (Nanjing) serves customers worldwide.

Voluntary Announcement
Inclusion Of Tinengotinib Tablets In The List Of Products
For Priority Review By The National Medical Products
Administration

Voluntary Announcement
Collaboration With Neurocrine

Announcements and Notices - [Inside Information]

Inside Information Announcement
Proposed Implementation Of The H Share Full
Circulation By The Company

Financial Statements/ESG Information - [Interim/Half-Year Report]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

TransThera Sciences (Nanjing) (2617 HK)

Voluntary Announcement Inclusion Of Tinengotinib Tablets In The List Of Products For Priority Review By The National Medical Products Administration

Voluntary Announcement Collaboration With Neurocrine

Inside Information Announcement Proposed Implementation Of The H Share Full Circulation By The Company

Interim Report 2025

Voluntary Announcement Unusual Price And Trading Volume Movements

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)